The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction – and help people ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction – and help people who already have one, a new study shows. Semaglutide (also known as Ozempic) ...

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding ...

Interest in GLP-1s for addiction has grown in the past decade, as some people prescribed them for diabetes or weight loss ...

The Group reported revenue growth of 7% (6% in constant currency) to $3.349 billion, compared to $3.127 billion in 2024 ...

A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin ...

Positioning The University of Texas at San Antonio as a national anchor for aging and longevity science, its Sam and Ann Barshop Institute for Longevity and Aging Studies will receive up to $38 ...

B.C. signed an agreement with the federal government a year ago to join the national pharmacare program, providing coverage ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction - and help people who already have one, a ...

SAN ANTONIO, Feb. 24, 2026 /PRNewswire/ — Positioning The University of Texas at San Antonio as a national anchor for aging and longevity science, its Sam and Ann Barshop Institute for Longevity and ...

The federal government is awarding up to $144 million in contracts to several universities and other research teams to study age-related illnesses and healthy longevity.